On June 24, 2020 Relay Therapeutics, a Phase 1 biotech developing small molecule therapies for solid tumors, reported that filed with the SEC to raise up to $200 million in an initial public offering (Press release, Relay Therapeutics, JUN 24, 2020, View Source [SID1234561437]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s lead candidate RLY-1971, an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), began a Phase 1 trial in patients with advanced solid tumors in the 1Q 2020. Relay is also planning to begin a Phase 1 trial of RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), in patients with advanced solid tumors having oncogenic FGFR2 alterations in the 2H 2020.

The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol RLAY. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.